Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22
Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society
Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation - Slideshow (NASDAQ:ELDN) 2026-06-22